21 November 2018 - - US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has strengthened its executive team with the appointment of Jason Ryan as chief operating and Financial officer, effective January 1, 2019, the company said.

Ryan joins Magenta from Foundation Medicine, where he served as chief financial officer.

During his tenure at Foundation, Ryan helped lead the company from early stage proof of concept to a global commercial organisation.

He was responsible for long-range planning and capital formation, and he played a key role in the company's relationship with, and sale to, Roche in July 2018.

Ryan also worked closely with the company's commercial leadership through several product launches and was deeply involved in Medicare and commercial payer reimbursement strategy and execution.

Prior to that, Ryan held management positions for Taligen Therapeutics, Codon Devices and Genomics Collaborative, and began his career at Deloitte and Touche. Ryan holds a B.S. in economics from Bates College and an M.B.A. from Babson College.

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases.